Equities analysts expect that BioTelemetry Inc (NASDAQ:BEAT) will announce $95.88 million in sales for the current fiscal quarter, Zacks reports. Two analysts have made estimates for BioTelemetry’s earnings, with the highest sales estimate coming in at $96.00 million and the lowest estimate coming in at $95.77 million. BioTelemetry reported sales of $58.13 million during the same quarter last year, which indicates a positive year over year growth rate of 64.9%. The firm is expected to report its next quarterly earnings report on Tuesday, August 14th.
According to Zacks, analysts expect that BioTelemetry will report full-year sales of $383.57 million for the current fiscal year, with estimates ranging from $381.85 million to $385.30 million. For the next fiscal year, analysts expect that the firm will report sales of $418.77 million per share, with estimates ranging from $414.23 million to $423.30 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research analysts that that provide coverage for BioTelemetry.
Get BioTelemetry alerts:
BioTelemetry (NASDAQ:BEAT) last posted its quarterly earnings results on Wednesday, April 25th. The medical research company reported $0.39 EPS for the quarter, beating the consensus estimate of $0.23 by $0.16. BioTelemetry had a negative net margin of 3.13% and a positive return on equity of 16.63%. The business had revenue of $94.50 million for the quarter, compared to analysts’ expectations of $91.55 million. During the same period in the previous year, the company posted $0.16 EPS. BioTelemetry’s revenue was up 69.1% on a year-over-year basis.
Several equities analysts have recently commented on BEAT shares. TheStreet cut shares of BioTelemetry from a “b-” rating to a “c” rating in a report on Tuesday, March 20th. BidaskClub upgraded shares of BioTelemetry from a “hold” rating to a “buy” rating in a report on Tuesday, April 17th. Zacks Investment Research cut shares of BioTelemetry from a “hold” rating to a “sell” rating in a report on Wednesday, January 31st. Dougherty & Co reiterated a “buy” rating and issued a $41.00 price objective (up from $40.00) on shares of BioTelemetry in a report on Friday, February 23rd. Finally, ValuEngine upgraded shares of BioTelemetry from a “hold” rating to a “buy” rating in a report on Friday, April 27th. Two research analysts have rated the stock with a sell rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $43.29.
In related news, SVP Peter Ferola sold 67,370 shares of the company’s stock in a transaction on Friday, May 11th. The shares were sold at an average price of $40.42, for a total value of $2,723,095.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, VP Heather C. Getz sold 36,405 shares of the company’s stock in a transaction on Wednesday, May 2nd. The stock was sold at an average price of $39.62, for a total transaction of $1,442,366.10. Following the completion of the sale, the vice president now owns 80,561 shares of the company’s stock, valued at $3,191,826.82. The disclosure for this sale can be found here. Insiders sold 263,503 shares of company stock valued at $10,153,267 over the last quarter. 8.30% of the stock is currently owned by corporate insiders.
A number of hedge funds have recently added to or reduced their stakes in BEAT. First Dallas Securities Inc. bought a new stake in BioTelemetry during the fourth quarter valued at about $133,000. Landscape Capital Management L.L.C. bought a new stake in BioTelemetry during the fourth quarter valued at about $248,000. Miles Capital Inc. bought a new stake in BioTelemetry during the first quarter valued at about $285,000. Teacher Retirement System of Texas bought a new stake in BioTelemetry during the fourth quarter valued at about $297,000. Finally, Pitcairn Co. boosted its holdings in BioTelemetry by 42.7% during the first quarter. Pitcairn Co. now owns 9,614 shares of the medical research company’s stock valued at $298,000 after acquiring an additional 2,875 shares during the period. Institutional investors own 86.21% of the company’s stock.
Shares of BioTelemetry stock traded up $0.25 on Tuesday, hitting $40.40. 267,726 shares of the company traded hands, compared to its average volume of 407,648. The company has a quick ratio of 1.83, a current ratio of 1.96 and a debt-to-equity ratio of 0.77. BioTelemetry has a 12-month low of $39.65 and a 12-month high of $40.40. The stock has a market cap of $1.32 billion, a P/E ratio of 41.65, a P/E/G ratio of 3.18 and a beta of 0.81.
BioTelemetry Company Profile
BioTelemetry, Inc, a mobile and wireless medical technology company, provides cardiac and mobile blood glucose monitoring (BGM), centralized medical imaging, and original equipment manufacturing services for the healthcare and clinical research industries. It operates in three segments: Healthcare, Research, and Technology.
Get a free copy of the Zacks research report on BioTelemetry (BEAT)
For more information about research offerings from Zacks Investment Research, visit Zacks.com